Lawrence Lee1, Pepa Kaneva, Eric Latimer, Liane S Feldman. 1. Department of Surgery, Steinberg-Bernstein Centre for Minimally Invasive Surgery and Innovation, McGill University Health Centre, Montreal, Canada.
Abstract
PURPOSE: The Gastrointestinal Quality of Life Index (GIQLI) is a disease-specific quality of life instrument that is commonly used in gastrointestinal disorders. However, no preference weights, which are used to calculate quality-adjusted life years for cost-effectiveness analyses, for this instrument have been assigned. Therefore, the objective of this study was to develop a mapping function to derive utility scores for the GIQLI. METHODS: Patients undergoing elective laparoscopic cholecystectomy completed the short-form 6D (SF-6D), a preference-weighted utility measure, and the GIQLI at baseline and at 1 wk and 1 mo postoperatively. The responsiveness of the SF-6D to expected postoperative changes as well as the correlation between the SF-6D and the GIQLI was investigated. Ordinary least squares regression was performed to derive a mapping function using the baseline values, which was then validated using postoperative values. Adjusted r(2), mean absolute error, and root mean square error was used to determine model performance. RESULTS: A total of 50 patients were included in the study (mean age 51.1 [standard deviation 16.8], 28% male). The SF-6D and GIQLI domains were responsive to expected postoperative changes, and there was high correlation between the SF-6D and four of the five GIQLI domains (excluding treatment effects). The final mapping function explained 63% of the variance in the derivation sample but had relatively high mean absolute error (0.075 and 0.067 in the 1-wk and 1-mo samples, respectively) and adjusted root mean square error (13.1% and 12.0% in the 1-wk and 1-mo samples, respectively). CONCLUSIONS: The GIQLI can be accurately mapped to SF-6D preference weights at the group level but may be too inexact at the individual level.
PURPOSE: The Gastrointestinal Quality of Life Index (GIQLI) is a disease-specific quality of life instrument that is commonly used in gastrointestinal disorders. However, no preference weights, which are used to calculate quality-adjusted life years for cost-effectiveness analyses, for this instrument have been assigned. Therefore, the objective of this study was to develop a mapping function to derive utility scores for the GIQLI. METHODS:Patients undergoing elective laparoscopic cholecystectomy completed the short-form 6D (SF-6D), a preference-weighted utility measure, and the GIQLI at baseline and at 1 wk and 1 mo postoperatively. The responsiveness of the SF-6D to expected postoperative changes as well as the correlation between the SF-6D and the GIQLI was investigated. Ordinary least squares regression was performed to derive a mapping function using the baseline values, which was then validated using postoperative values. Adjusted r(2), mean absolute error, and root mean square error was used to determine model performance. RESULTS: A total of 50 patients were included in the study (mean age 51.1 [standard deviation 16.8], 28% male). The SF-6D and GIQLI domains were responsive to expected postoperative changes, and there was high correlation between the SF-6D and four of the five GIQLI domains (excluding treatment effects). The final mapping function explained 63% of the variance in the derivation sample but had relatively high mean absolute error (0.075 and 0.067 in the 1-wk and 1-mo samples, respectively) and adjusted root mean square error (13.1% and 12.0% in the 1-wk and 1-mo samples, respectively). CONCLUSIONS: The GIQLI can be accurately mapped to SF-6D preference weights at the group level but may be too inexact at the individual level.
Authors: Toby O Steele; Jess C Mace; Raj Dedhia; Luke Rudmik; Timothy L Smith; Jeremiah A Alt Journal: Int Forum Allergy Rhinol Date: 2016-06-16 Impact factor: 3.858
Authors: Stavros Petrou; Oliver Rivero-Arias; Helen Dakin; Louise Longworth; Mark Oppe; Robert Froud; Alastair Gray Journal: Pharmacoeconomics Date: 2015-10 Impact factor: 4.981
Authors: Stavros Petrou; Oliver Rivero-Arias; Helen Dakin; Louise Longworth; Mark Oppe; Robert Froud; Alastair Gray Journal: Pharmacoeconomics Date: 2015-10 Impact factor: 4.981
Authors: Stavros Petrou; Oliver Rivero-Arias; Helen Dakin; Louise Longworth; Mark Oppe; Robert Froud; Alastair Gray Journal: Health Qual Life Outcomes Date: 2015-08-01 Impact factor: 3.186
Authors: Stavros Petrou; Oliver Rivero-Arias; Helen Dakin; Louise Longworth; Mark Oppe; Robert Froud; Alastair Gray Journal: Appl Health Econ Health Policy Date: 2015-10 Impact factor: 2.561
Authors: Stavros Petrou; Oliver Rivero-Arias; Helen Dakin; Louise Longworth; Mark Oppe; Robert Froud; Alastair Gray Journal: Qual Life Res Date: 2015-08-01 Impact factor: 4.147
Authors: Stavros Petrou; Oliver Rivero-Arias; Helen Dakin; Louise Longworth; Mark Oppe; Robert Froud; Alastair Gray Journal: Int J Technol Assess Health Care Date: 2015-08-03 Impact factor: 2.188